<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542331</url>
  </required_header>
  <id_info>
    <org_study_id>2017.lipiodol.flush</org_study_id>
    <nct_id>NCT03542331</nct_id>
  </id_info>
  <brief_title>Endometrial Effects of Lipiodol</brief_title>
  <official_title>Histological and Transcriptional Changes Caused by Endometrial Flushing With Lipiodol: A Cross Over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal is to investigate whether endometrial flushing with Lipiodol enhances fertility.
      Therefore, anatomo-pathological, histochemical and transcriptional changes of the endometrium
      after Lipiodol bathing in a general population of healthy volunteers will be determined.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-centre, cross-over, open-label trial will be performed. Healthy volunteers,
      fulfilling the inclusion/exclusion criteria, will be asked to do blood samples and
      ultrasounds for the detection of the LH (luteinizing hormone) surge in a natural cycle. The
      intervention group will undergo endometrial flushing with Lipiodol between day 6 and 8 of the
      cycle, while the control group between day 6 and 8 of the cycle will have a mock catheter
      introduction without any Lipiodol flush. An endometrial biopsy will be performed 7 days after
      the LH peak in all the participants. Furthermore, all the participants will undergo one cycle
      with flushing and one cycle with introduction of a mock catheter but without flushing with
      any medication. The wash-out period between the 2 biopsies will be 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anatomo-pathological changes of the endometrium after Lipiodol bathing</measure>
    <time_frame>7 days after LH peak</time_frame>
    <description>To determine whether the treatment with lipiodol alters the leukocyte population. Changes in the uterine dendritic cell population, collections of macrophages and an increased number of inflammatory cells will be investigated. A sub-ephitelial re-location of lymphocytes (CD3-CD7 and CD8 (CD: Cluster of Differentiation)) will be looked for.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Histochemical changes of the endometrium after Lipiodol bathing</measure>
    <time_frame>7 days after LH peak</time_frame>
    <description>The immunohistochemistry for the key implantation factors, the subsequent molecular markers will be examined: estrogen receptors (ER) (α/β), progesterone receptors (PR) (A, B), prolactine (PRL), insulin-like growth factor binding protein-1 (IGF-BP1), leukaemia inhibitory factor (LIF), Mucins (MUC1), integrin αVβ3, vascular endothelial growth factor (VEG-F), transforming growth factor (TGF-β1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transcriptional changes of the endometrium after Lipiodol bathing</measure>
    <time_frame>7 days after LH peak</time_frame>
    <description>RNA sequencing</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Female Infertility</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The control group wille have a mock catheter introduction between day 6 and 8 of the cycle without any Lipiodol flush</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group will undergo endometrial flushing with Lipiodol between day 6 and 8 of the cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipiodol</intervention_name>
    <description>Endometrial flushing with Lipiodol between day 6 and 8 of the cycle</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mock catheter</intervention_name>
    <description>Introduction of a mock catheter in the uterus between day 6 and 8 of the cycle</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged ≥18 and &lt;36 years

          -  Regular cycle (25-35 days)

          -  Signed informed consent

          -  Participants can be included only once in the trial

          -  Contraceptive: barrier method only.

        Exclusion Criteria:

          -  known iodine allergy

          -  Body mass index 30 or ≤18.5

          -  Smoking

          -  Previous diagnosis of PCO (Polycystic Ovary Syndrome) (&gt;12 antral follicles in one
             ovary, Rotterdam criteria 2003)

          -  Previous diagnosis of endometriosis, uterine malformations or intrauterine pathologies
             (submucosal fibroids, endometrial polyps, and intrauterine adhesions)

          -  Systemic diseases such as thyroid dysfunction

          -  Breast-feeding or pregnancy within the last 6 months

          -  Intrauterine devices (IUD)

          -  History of recurrent miscarriage

          -  Known history of infertility

          -  Previous uterine surgery

          -  Pregnancy wish during the course of the study

          -  Women who have been previously enrolled in the trial

          -  Those unable to comprehend the investigational nature of the proposed study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christophe Blockeel, PhD</last_name>
    <phone>+3224776699</phone>
    <email>christophe.blockeel@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sylvie De Rijdt, MD</last_name>
    <email>sylvie.derijdt@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Blockeel, PhD</last_name>
      <phone>+3224776699</phone>
      <email>christophe.blockeel@uzbrussel.Be</email>
    </contact>
    <contact_backup>
      <last_name>Sylvie De Rijdt, MD</last_name>
      <email>sylvie.derijdt@uzbrussel.be</email>
    </contact_backup>
    <investigator>
      <last_name>Christophe Blockeel, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annalisa Racca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>May 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>May 3, 2019</last_update_submitted>
  <last_update_submitted_qc>May 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethiodized Oil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

